Adila Izgutdina

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

This paper develops dual-antigen targeting CAR-T cells against CD70 and active integrin β2 to overcome AML antigen heterogeneity and reduce off-tumor toxicity.

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.